We Accept amex

Formerly known as Maylips.com

info@directdoctorsupply.com+1-800-325-7104

Logo Logo
Track delivery Wishlist
  • 0 $ 0.00
  • Products
    • All Products
    • Peptides NEW
    • Anaesthetics
    • Body Sculpting
    • Botulinum Toxin
    • Cannulas and Needles
    • Cellular Rejuvenation
    • Dermal Filler Removal
    • Dermal Fillers
      • Biostimulators
      • HA Dermal Fillers
      • Korean Dermal Fillers
      • Polynucleotides
      • Skinboosters
    • Exosomes
    • Eyelash Enhancers
    • Fat Removal
    • Gynecology
    • Mesotherapy
    • IV Therapy
    • Orthopedic Injections
    • Peels and Masks
    • PRP Kits
    • Skincare
    • Threads
      • PCLA Threads
      • PDO Threads
      • PLA Threads
    • Weight Loss
  • Brands
    • ALIAXIN®
    • ALIDYA™
    • AQUALYX®
    • AZZALURE®
    • BCN
    • BELLAST®
    • BELOTERO®
    • BIOREPEELCL3®
    • BOCOUTURE® (XEOMIN®)
    • BOTOX®
    • CAREGEN
    • CINGAL®
    • CRESPINE®
    • CROMA
    • CYTOCARE
    • DEPO-PROVERA®
    • DERMALAX™
    • DESIRIAL®
    • DUROLANE®
    • DYSPORT®
    • EJAL
    • ELLANSÉ™
    • EMLA™
    • Euflexxa
    • FILLMED®
    • FILORGA®
    • GARDASIL®
    • HArmonyCA™
    • HYACORP
    • HYAFILIA®
    • HYALGAN®
    • HYMOVIS®
    • HYNIDASE®
    • INTRALINE®
    • JALUPRO®
    • JAYDESS®
    • JUVÉDERM®
    • KARISMA
    • LEMONBOTTLE
    • LANLUMA
    • LIPORASE®
    • MEDIDERMA®
    • MESO-RELLE®
    • MESOESTETIC®
    • MICRONJET™
    • MIRENA®
    • MONOVISC®
    • MOUNJARO®
    • NEAUVIA™
    • NEURAMIS®
    • NEXPLANON®
    • NITHYA
    • NOVERA COMPOUNDS
    • NUCLEOFILL™
    • ORTHOVISC®
    • OZEMPIC®
    • PERFECTHA®
    • PLASMOLIFTING™
    • PROFHILO®
    • ​PROSTROLANE®
    • PRX-T33®
    • RADIESSE®
    • RAINBOW
    • REFINE
    • REJURAN®
    • REJUVANAD+
    • REFINE
    • RESTYLANE®
    • REVANESSE®
    • REVOFIL
    • REVOLAX™
    • SAXENDA®
    • SAYPHA®
    • SCULPTRA®
    • SESDERMA®
    • SILHOUETTE
    • SMB®
    • SOFTFIL®
    • STYLAGE®
    • SUNEKOS®
    • SUPARTZ®
    • SYNVISC®
    • T-SAFE®
    • TEOSYAL®
    • ​THERASET®
    • VISCODERM®
    • WEGOVY®
    • XEOMIN®
    • ZO®
  • Peptides NEW
  • Sale
  • Shipping
  • Contact
  • About Us
  • Referral Program
  • Blog
  • Sign In / Register
Logo Logo
Menu
Close
Wishlist
  • Products
    • All Products
    • Peptides NEW
    • Anaesthetics
    • Body Sculpting
    • Botulinum Toxin
    • Cannulas and Needles
    • Cellular Rejuvenation
    • Dermal Filler Removal
    • Dermal Fillers
      • Biostimulators
      • HA Dermal Fillers
      • Korean Dermal Fillers
      • Polynucleotides
      • Skinboosters
    • Exosomes
    • Eyelash Enhancers
    • Fat Removal
    • Gynecology
    • Mesotherapy
    • IV Therapy
    • Orthopedic Injections
    • Peels and Masks
    • PRP Kits
    • Skincare
    • Threads
      • PCLA Threads
      • PDO Threads
      • PLA Threads
    • Weight Loss
  • Brands
    • ALIAXIN®
    • ALIDYA™
    • AQUALYX®
    • AZZALURE®
    • BCN
    • BELLAST®
    • BELOTERO®
    • BIOREPEELCL3®
    • BOCOUTURE® (XEOMIN®)
    • BOTOX®
    • BOTULAX®
    • CAREGEN
    • CINGAL®
    • CRESPINE®
    • CROMA
    • CYTOCARE
    • DEPO-PROVERA®
    • DERMALAX™
    • DESIRIAL®
    • DUROLANE®
    • DYSPORT®
    • EJAL
    • ELLANSÉ™
    • EMLA™
    • Euflexxa
    • FILLMED®
    • FILORGA®
    • GARDASIL®
    • HArmonyCA™
    • HYACORP
    • HYAFILIA®
    • HYALGAN®
    • HYMOVIS®
    • HYNIDASE®
    • INNOTOX®
    • INTRALINE®
    • JALUPRO®
    • JAYDESS®
    • JUVÉDERM®
    • KAIMAX
    • KARISMA
    • LEMONBOTTLE
    • LETYBO®
    • LANLUMA
    • LIPORASE®
    • LIZTOX®
    • MEDIDERMA®
    • MEDITOXIN®
    • MESO-RELLE®
    • MESOESTETIC®
    • MICRONJET™
    • MIRENA®
    • MONOVISC®
    • MOUNJARO®
    • NABOTA® (JEUVEAU®)
    • NEAUVIA™
    • NEURAMIS®
    • NEXPLANON®
    • NITHYA
    • NOVERA COMPOUNDS
    • NUCLEOFILL™
    • ORTHOVISC®
    • OZEMPIC®
    • PERFECTHA®
    • PLASMOLIFTING™
    • PROFHILO®
    • ​PROSTROLANE®
    • PRX-T33®
    • RADIESSE®
    • RAINBOW
    • Re N Tox™
    • REFINE
    • REJURAN®
    • REJUVANAD+
    • REFINE
    • RESTYLANE®
    • REVANESSE®
    • REVOFIL
    • REVOLAX™
    • SAXENDA®
    • SAYPHA®
    • SCULPTRA®
    • SESDERMA®
    • SILHOUETTE
    • SMB®
    • SOFTFIL®
    • STYLAGE®
    • SUNEKOS®
    • SUPARTZ®
    • SYNVISC®
    • T-SAFE®
    • TEOSYAL®
    • ​THERASET®
    • VISCODERM®
    • WEGOVY®
    • XEOMIN®
    • ZO®
  • Peptides NEW
  • Sale
  • Shipping
  • Contact
  • About Us
  • Referral Program
  • Blog
  • Sign In / Register
  • 0 $ 0.00
Direct Doctor SupplyPeptides for ResearchMuscle Growth & Performance PeptidesTesamorelin
Product Category
  • Anaesthetics (2)
  • Body Sculpting (4)
  • Botulinum Toxins (33)
  • Cannulas and Needles (13)
  • Cellular Rejuvenation (1)
  • Dermal Filler Removal (2)
  • Dermal Fillers (192)
  • Biostimulators (10)
  • HA Dermal Fillers (129)
  • Korean Dermal Fillers (28)
  • Polynucleotides (17)
  • Skinboosters (16)
  • Exosomes (1)
  • Eyelash Enhancers (1)
  • Fat Removal (3)
  • Gynecology (8)
  • IV Therapy (2)
  • Mesotherapy (23)
  • Orthopedic Injections (11)
  • Peels and Masks (23)
  • Peptides for Research (45)
  • Aesthetic & Cosmetic Peptides (1)
  • Brain, Cognitive & Nootropic Peptides (4)
  • Healing & Regenerative Peptides (6)
  • Immune & Thymic Peptides (4)
  • Longevity & Anti-Aging Peptides (7)
  • Muscle Growth & Performance Peptides (11)
  • Sexual Health & Hormonal Peptides (3)
  • Weight Loss & Metabolic Peptides (11)
  • PRP Kits (1)
  • Skincare (26)
  • Threads (28)
  • PCLA Threads (3)
  • PDO Threads (20)
  • PLA Threads (3)
  • Weight Loss (24)
Product Brand
  • ALIAXIN® (6)
  • ALIDYA™ (1)
  • AQUALYX® (1)
  • AZZALURE® (1)
  • BCN (12)
  • BELLAST® (3)
  • BELOTERO® (7)
  • BIOMEDICO (3)
  • BIOREPEELCL3® (2)
  • BOCOUTURE® (XEOMIN®) (3)
  • BOTOX® (6)
  • CAREGEN (2)
  • CINGAL® (1)
  • CRESPINE® (1)
  • CROMA (4)
  • CYTOCARE (4)
  • DEPO-PROVERA® (1)
  • DERMALAX™ (3)
  • DESIRIAL® (2)
  • DUROLANE® (1)
  • DYSPORT® (4)
  • EJAL (1)
  • ELLANSÉ™ (2)
  • EMLA™ (2)
  • EUFLEXXA® (1)
  • EXOJUV (1)
  • FILLMED® (14)
  • FILORGA® (2)
  • GARDASIL® (1)
  • HArmonyCA™ (1)
  • HYACORP (5)
  • HYAFILIA® (2)
  • HYALGAN® (1)
  • HYMOVIS® (1)
  • HYNIDASE® (1)
  • INTRALINE® (24)
  • JALUPRO® (5)
  • JAYDESS® (1)
  • JUVÉDERM® (13)
  • KARISMA (1)
  • LANLUMA (1)
  • LEMONBOTTLE (1)
  • LIPORASE® (1)
  • MEDIDERMA® (26)
  • MESO-RELLE® (2)
  • MESOESTETIC® (2)
  • MICRONJET™ (1)
  • MIRENA® (1)
  • MONOVISC® (1)
  • MOUNJARO® (9)
  • NEAUVIA™ (11)
  • NEURAMIS® (1)
  • NEXPLANON® (2)
  • NITHYA (3)
  • NOVERA COMPOUNDS (46)
  • NUCLEOFILL™ (8)
  • ORTHOVISC® (1)
  • OZEMPIC® (8)
  • PERFECTHA® (4)
  • PLASMOLIFTING™ (1)
  • PLINEST® (5)
  • PROFHILO® (3)
  • ​PROSTROLANE® (1)
  • PRX-T33® (1)
  • RADIESSE® (3)
  • RAINBOW (7)
  • REFINE (3)
  • REJURAN® (3)
  • REJUVANAD+ (2)
  • RENEFIL (3)
  • RESTYLANE® (10)
  • REVANESSE® (6)
  • REVOFIL (9)
  • REVOLAX™ (4)
  • SAXENDA® (1)
  • SAYPHA® (6)
  • SCULPTRA® (1)
  • SESDERMA® (10)
  • SILHOUETTE (3)
  • SMB® (1)
  • SOFTFIL® (6)
  • STYLAGE® (25)
  • SUNEKOS® (4)
  • SUPARTZ® (1)
  • SYNVISC® (2)
  • T-SAFE® (1)
  • TEOSYAL® (12)
  • ​THERASET® (1)
  • ULTRA V® (1)
  • VISCODERM® (2)
  • WEGOVY® (6)
  • XEOMEEN® (1)
  • XEOMIN® (4)
  • ZO® (3)

Tesamorelin

Showing all 5 results

Sort By:
  • Tesamorelin 10mg + Ipamorelin 2mg 12mg FrontTesamorelin 10mg + Ipamorelin 2mg 12mg Back
    2X Blend: Tesamorelin 10mg + Ipamorelin 2mg
    $ 95.00
    Read More
    -+
  • Tesamorelin 10mg FrontTesamorelin 10mg Back
    Tesamorelin 10mg
    $ 90.00
    Read More
    -+
  • Tesamorelin 10mg+Ipamorelin3mg FrontTesamorelin 10mg+Ipamorelin 3mg Back
    Tesamorelin 10mg + Ipamorelin 3mg
    $ 99.00
    Read More
    -+
  • Coming Soon
    Tesamorelin 5mg FrontTesamorelin 5mg Back
    Tesamorelin 5mg
    Read More
  • Coming Soon
    Tesamorelin 8mg FrontTesamorelin 8mg Back
    Tesamorelin 8mg
    Read More

Tesamorelin is the only FDA-approved GHRH analogue on the market, developed to optimize growth hormone and enhance body composition. Marketed as Egrifta and Egrifta SV, it is evaluated by HIV medicine specialists, endocrinologists, anti-aging clinicians, and sports medicine physicians. For those looking to buy tesamorelin online, Direct Doctor Supply maintains the highest standards of purity and supply reliability. This guide provides evidence-based information on mechanisms, dosing, safety, and comparisons with related GHRH analogues.

Tesamorelin Benefits & FDA Approval: Visceral Fat, Body Composition & GH Optimization

Tesamorelin (Egrifta/Egrifta SV) is an FDA-approved synthetic 44-amino acid GHRH analogue and the only FDA-approved growth hormone-releasing hormone analogue currently marketed in the United States [5]. It is indicated for the reduction of excess visceral fat in the stomach area in HIV-infected adults with lipodystrophy, a distinction that gives it the strongest regulatory and evidence foundation of any compound in its class [2]. Off-label applications in body composition and GH optimization are evaluated at prescriber discretion.

Its FDA approval was based on two pivotal Phase 3 randomized, placebo-controlled clinical trials, which demonstrated statistically significant reductions in visceral fat compared with placebo [1], [2]. Off-label use at prescriber discretion is permitted within the US regulatory framework, though such applications fall outside the validated indication and require care team oversight.

Tesamorelin Benefits

The primary FDA-approved benefit of tesamorelin is selective reduction of visceral adipose tissue in the abdominal cavity, which is a clinically meaningful distinction from total body weight loss [1], [3]. Visceral fat reduction improves metabolic risk factors including insulin sensitivity, lipid profiles, and inflammatory markers [4].

Secondary elevation of IGF-1 supports bone density and metabolic function within the approved indication [1]. Additional applications are addressed separately under practitioner-reported and off-label considerations below.

Tesamorelin Before and After: Phase 3 RCT Evidence

In the two pivotal Phase 3 randomized, placebo-controlled trials (Study 1 and Study 2), patients treated with tesamorelin achieved a mean reduction in visceral adipose tissue (VAT) of approximately 18% in Study 1 and 14% in Study 2, compared to baseline [1], [2]. These results are study outcomes and do not represent a guaranteed individual result. Corresponding improvements in insulin resistance and triglyceride levels were also observed [4]. These studies provide the highest level of clinical evidence available for any GHRH analogue.

Practitioner-Reported and Off-Label Considerations

While the primary evidence base for tesamorelin is limited to the approved HIV-lipodystrophy indication, some practitioners report evaluating it off-label for body composition enhancement, with evidence extrapolated from the approved indication. While some practitioners report utilizing tesamorelin off-label for muscle mass preservation or recovery metrics, these applications have not been evaluated or validated by the FDA [5]. Off-label protocols typically use a daily subcutaneous dose of 1.4 mg, though no validated protocol exists outside the approved indication. Care team oversight, baseline metabolic assessment, and periodic monitoring of IGF-1 and glucose are advised for any off-label application.

Weight Loss and Visceral Fat Reduction: Mechanistic Distinction

Tesamorelin selectively reduces visceral adipose tissue while having minimal effect on subcutaneous fat, improving cardiometabolic risk independent of total body weight change [1], [3]. This distinction is clinically important: reductions in visceral fat represent a metabolic benefit that does not necessarily correspond to overall weight loss on the scale.

How Tesamorelin Works: GHRH Mechanism & Growth Hormone Stimulation

Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs, triggering pulsatile endogenous growth hormone release into circulation [5]. It is designed to mimic endogenous GHRH activity and support native pulsatile release pathways. Growth hormone promotes visceral lipolysis, increases circulating IGF-1, and enhances protein synthesis. Pituitary somatostatin feedback remains intact, retaining native negative feedback mechanisms [5].

It selectively reduces visceral fat deposits in the abdominal cavity with minimal effect on subcutaneous fat, a clinically meaningful distinction confirmed by Phase 3 trial data [1], [3]. The peptide increases circulating IGF-1 levels, supporting bone density and metabolic function within the approved indication [1].

Half-Life, Receptor Dynamics and Pulsatility

Tesamorelin has an elimination half-life of approximately 8 minutes after subcutaneous administration, as stated in the FDA prescribing information [5]. This pharmacokinetic profile supports once-daily injection and is designed to support native pulsatile GH release patterns. By retaining native negative feedback mechanisms, the compound avoids the continuous exposure to secretagogues associated with longer-acting formulations. For reference, Sermorelin has an approximate half-life of 10–20 minutes, while CJC-1295 with DAC modification has an approximate half-life of 8 days [5].

Tesamorelin Dosage & Injection Protocol

The current FDA-approved dose for Egrifta SV is 1.4 mg once daily via subcutaneous injection [5]. An earlier formulation utilized a 2 mg dose, but the current standard of care reflects the 1.4 mg Egrifta SV formulation. Injection uses appropriate needles and syringes and should be administered into the abdomen, thigh, or upper arm with site rotation to minimize injection site reactions. Practitioners should avoid injecting into areas of scar tissue or active inflammation [5].

Off-Label Dosing Considerations

Practitioners evaluating off-label tesamorelin protocols typically reference the approved 1.4 mg daily subcutaneous dose as a starting point [5]. No validated dosing protocol exists outside the approved indication, and all off-label dosing references should be understood as practitioner-reported rather than clinically validated. Care team oversight is essential for off-label applications, and baseline assessment of metabolic parameters, including fasting glucose, lipid panel, and IGF-1, is recommended with periodic re-monitoring.

Storage, Reconstitution and Handling

Tesamorelin vials require refrigeration at 2–8°C before reconstitution [5]. Once reconstituted with the provided diluent, the solution must be used immediately, and any unused portion must be discarded [5]. Injection sites should be rotated among the abdomen, thigh, and upper arm to minimize localized reactions.

Is Tesamorelin Safe? Side Effects & Legal Status

The safety of tesamorelin is established by extensive Phase 3 randomized, placebo-controlled trial data from Studies 1 and 2 [1], [2]. The adverse event profile is well-characterized and generally manageable with appropriate monitoring.

Common Tesamorelin Side Effects

Adverse events reported in the Phase 3 trials include [5]:

  • Peripheral edema, reported in approximately 6.1% of patients receiving tesamorelin compared to 2.2% in the placebo group; growth hormone-mediated and dose-dependent
  • Arthralgias and carpal tunnel syndrome, reflecting systemic GH elevation effects
  • Injection site reactions: erythema reported in approximately 8.5% of patients and pruritus in approximately 6.1%; typically transient

IGF-1 and Glucose Monitoring

Baseline and periodic measurement of serum IGF-1 and fasting glucose are recommended, particularly for off-label applications and in patients with metabolic risk factors [4], [5]. Tesamorelin may impair glucose tolerance or unmask latent diabetes in susceptible individuals [5]. IGF-1 levels above age-adjusted reference ranges should prompt dose reduction or reassessment of the balance between clinical benefit and risk [4].

US Legal Status and Regulatory Designation

In the United States, tesamorelin is FDA-approved (Egrifta/Egrifta SV) for reducing visceral fat in HIV lipodystrophy [5]. While tesamorelin is not on the FDA 503A Bulk Drug Substances List, it remains eligible for compounding under Section 503A because it is an active component of an FDA-approved drug (Egrifta) [5]. Off-label prescription and use by licensed practitioners is legally permissible at their clinical discretion, and compounding pharmacies may prepare tesamorelin under proper licensure and regulatory oversight. Practitioners should verify current federal, state, and institutional requirements before implementation, as regulatory guidance may evolve.

WADA Status and Competitive Athletes

As a GH secretagogue, tesamorelin is prohibited at all times, both in- and out-of-competition, under Section S2 of the WADA Prohibited List [5]. Practitioners should explicitly advise competitive athletes of this prohibition before any consideration of protocols. Off-competition therapeutic use may be permissible under the Therapeutic Use Exemption (TUE) process with appropriate documentation; athletes and practitioners should verify current WADA classifications directly before proceeding.

Sourcing Tesamorelin: Guidance for Licensed Practitioners

Tesamorelin is a prescription compound and an FDA-approved therapeutic, available only to qualified licensed medical professionals. It is not available for general consumer purchase. Sourcing from suppliers with appropriate regulatory standing is essential to ensure product quality, sterility, and documentation integrity.

When evaluating suppliers, practitioners should confirm:

  • A valid certificate of analysis (CoA) from an accredited third-party laboratory
  • LOT number traceability for each batch
  • Sterility and endotoxin testing documentation
  • Cold-chain integrity and stability data appropriate to a lyophilized injectable compound

Practitioners seeking to buy tesamorelin online or identify a verified compounding pharmacy or research-grade supplier may contact the Direct Doctor Supply support team for sourcing guidance and documentation. The support team can connect practitioners with suppliers meeting appropriate purity and traceability standards. For those evaluating how to buy tesamorelin wholesale for larger clinical networks, the Direct Doctor Supply support team can provide guidance on supplier comparison and documentation requirements. Contact the Direct Doctor Supply support team directly for sourcing direction.

Tesamorelin vs Sermorelin & CJC-1295

Tesamorelin vs Sermorelin

Both tesamorelin and Sermorelin are GHRH analogues, but tesamorelin is the only one currently marketed in the United States with active FDA approval and Phase 3 visceral fat RCT data; Sermorelin was previously approved but is no longer actively manufactured [2], [5]. Tesamorelin’s elimination half-life of approximately 8 minutes after subcutaneous administration and its once-daily dosing are designed to mimic endogenous GHRH activity; Sermorelin’s similar short half-life has historically aligned with nightly administration designed to mirror the body’s natural GH secretion pattern.

For practitioners for whom active FDA approval and validated Phase 3 clinical evidence are decisive factors, tesamorelin is the stronger choice. Qualified researchers who plan to buy Sermorelin as an alternative should note the regulatory distinction and the lack of an approved active indication.

Tesamorelin vs CJC-1295

Tesamorelin (elimination half-life approximately 8 minutes after subcutaneous administration, once-daily dosing, FDA-approved, Phase 3 visceral fat data) and CJC-1295 (DAC-modified, approximately 8-day half-life, once-weekly dosing, no approved indication) represent fundamentally different engineering approaches to GHRH agonism [5]. Tesamorelin provides the strongest evidence base and regulatory standing of any GHRH analogue currently marketed in the United States.

Practitioners requiring evidence-based protocols should select tesamorelin; those prioritizing compliance and sustained GH elevation may favor CJC-1295. Before practitioners choose to buy CJC-1295 or other research peptides, they should compare options based on detailed protocol context.

FAQs

What is Tesamorelin, and is it FDA-approved?

Tesamorelin (Egrifta/Egrifta SV) is a synthetic GHRH analogue and the only FDA-approved growth hormone-releasing hormone analogue currently marketed in the United States, indicated for visceral fat reduction in HIV-positive patients with lipodystrophy [2], [5]. Off-label use for body composition and GH optimization is permitted at prescriber discretion, though these applications have not been evaluated or validated by the FDA.

How does Tesamorelin work to reduce visceral fat?

Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs, triggering pulsatile GH release that mimics endogenous GHRH activity and supports native pulsatile release pathways [5]. Growth hormone promotes selective lipolysis in visceral adipose tissue with minimal effect on subcutaneous fat, while native negative feedback mechanisms are retained at approved doses [1], [3].

What is the standard Tesamorelin dosage for approved use?

The current FDA-approved dose for Egrifta SV is 1.4 mg once daily via subcutaneous injection [5]. Once reconstituted with the provided diluent, the solution must be used immediately and any unused portion discarded. Off-label applications are reported only by practitioners and require oversight by the care team.

What side effects should I monitor with Tesamorelin?

Common side effects include peripheral edema (approximately 6.1% of treated patients vs. 2.2% placebo), arthralgias, and carpal tunnel syndrome, all generally dose-dependent and GH-mediated [5]. Localized injection site reactions include erythema (8.5%) and pruritus (6.1%). Baseline and periodic monitoring of IGF-1 and glucose are recommended [4], [5].

How does Tesamorelin compare to Sermorelin?

Tesamorelin has active FDA approval based on Phase 3 visceral fat RCT data; Sermorelin was previously approved but is no longer actively manufactured [2], [5]. Both have short half-lives that support pulsatile GH release. Tesamorelin represents the stronger current regulatory and evidence standard.

How does Tesamorelin compare to CJC-1295?

Tesamorelin is FDA-approved, with an elimination half-life of approximately 8 minutes after subcutaneous administration, and supported by validated Phase 3 evidence [5]. CJC-1295 is a research compound with an approximately 8-day half-life and once-weekly dosing. Tesamorelin offers stronger regulatory standing; CJC-1295 offers dosing convenience for research applications.

References

  1. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311–322. https://pubmed.ncbi.nlm.nih.gov/20101189/
  2. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490
  3. Lake JE, La K, Erlandson KM, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. doi:10.1097/QAD.0000000000002897
  4. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. doi:10.1093/cid/cis251
  5. S. Food and Drug Administration. Egrifta (tesamorelin for injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505Orig1s010lbl.pdf

All content on this website is intended for informational purposes and does not constitute medical advice.

Content prepared by Direct Doctor Supply’s editorial team.

Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.

SVG Logo Color cropped

info@directdoctorsupply.com

+1-800-325-7104

Book a MeetingTrack delivery
Trustpilot

Supported payment providers

Visa Mastercard American Express Google Pay Apple Pay

*Apple Pay and Google Pay are available via a personalized link provided by your account manager.

🔒 Transactions on this website meet strict PCI DSS compliance for your safety.

Product authenticity guaranteed: all products are sourced from licensed distributors and traceable by LOT number.

Company
  • About Us
  • FAQ
  • Contact Us
  • Referral Program
  • Sitemap
Follow Us
  • Facebook
  • Instagram
  • LinkedIn
Company
  • About Us
  • FAQ
  • Contact Us
  • Referral Program
Follow Us
  • Facebook
  • Instagram
  • Linkedin
Products
  • Anaesthetics
  • Body Sculpting
  • Botulinum Toxin
  • Needles and Cannula
  • Filler Removal
  • Dermal Fillers
  • Eyelash Enhancers
  • Fat Removal
  • Gynecology
  • Mesotherapy
  • Orthopaedic Injections
  • Peels and Masks
  • PRP Kits
  • Skincare
  • Threads
  • Weight Management
Products
  • Anaesthetics
  • Body Sculpting
  • Botulinum Toxin
  • Needles and Cannula
  • Filler Removal
  • Dermal Fillers
  • Eyelash Enhancers
  • Fat Removal
  • Gynecology
  • Mesotherapy
  • Orthopaedic Injections
  • Peels and Masks
  • PRP Kits
  • Skincare
  • Threads
  • Weight Management

All peptide products sold by Direct Doctor Supply are Research Use Only (RUO) and intended solely for laboratory and scientific research. They are not FDA-approved and not for human or veterinary use, clinical, diagnostic, or therapeutic purposes. By purchasing RUO materials, you confirm they will be handled by qualified personnel in a proper research setting and in compliance with regulations. Products must not be administered to humans or animals or represented as safe or effective for medical use. Use is at your own risk; Direct Doctor Supply assumes no liability for misuse or regulatory issues.

2026 Direct Doctor Supply All rights reserved.
Terms Of Use Privacy Policy Refund and Replacement Shipping & Delivery